Company Description
Finch Therapeutics Group, Inc., a clinical-stage microbiome therapeutics company, develops a novel class of orally administered biological drugs in the United States.
The company develops FIN-211, a microbiome candidate designed to address the gastrointestinal and behavioral symptoms of autism spectrum disorder; and FIN-524 for the prevention, diagnosis, theragnosis or treatment of diseases in humans, including ulcerative colitis; FIN-525 for the treatment of Crohn's disease; and other microbiome product candidates.
The company has collaboration and license agreements with Takeda Pharmaceutical Company Limited; and license agreements with Skysong Innovations LLC, OpenBiome, Arizona State University, and University of Minnesota.
Finch Therapeutics Group, Inc. was incorporated in 2014 and is based in Boston, Massachusetts.
| Country | United States |
| Founded | 2017 |
| IPO Date | Mar 19, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 1 |
| CEO | Matthew P. Blischak J.D. |
Contact Details
Address: 75 State Street, Suite 100 Boston, Massachusetts 02109 United States | |
| Phone | 617-229-6499 |
| Website | finchtherapeutics.com |
Stock Details
| Ticker Symbol | FNCH |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $17.00 |
| CIK Code | 0001733257 |
| CUSIP Number | 31773D101 |
| ISIN Number | US31773D2009 |
| Employer ID | 82-3433558 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Matthew P. Blischak J.D. | Chief Executive Officer |
| Lance Thibault CPA | Chief Financial Officer |
| James S. Sigler MBA | Executive Vice President of CMC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| May 17, 2024 | 8-K | Current Report |
| May 10, 2024 | 10-Q | Quarterly Report |
| Apr 26, 2024 | 10-K/A | [Amend] Annual report |
| Apr 3, 2024 | 8-K | Current Report |
| Mar 28, 2024 | 144 | Filing |
| Mar 25, 2024 | 10-K | Annual Report |
| Feb 23, 2024 | 8-K | Current Report |
| Dec 13, 2023 | SC 13G | Statement of acquisition of beneficial ownership by individuals |
| Nov 22, 2023 | 144 | Filing |
| Nov 17, 2023 | 8-K | Current Report |